

Status of surviving patients at their last follow up		n = 215	
Clinical status		ECG	Echocardiography
NYHA-classification		Sinus rhythm 196 (91.2%)	residual shunt 24 (11.2%)
NYHA I	189 (87.9%)	AV block I° 14 (6.5%)	LVOTO 11 (5.1%)
NYHA II	20 (9.3%)	AV block III° 3 (1.4%)	Left ventricle
NYHA III	5 (2.3%)	Ectopic rhythm 8 (3.7%)	good systolic function 210 (97.7%)
NYHA IV	1 (0.5%)	Sick-Sinus-Syndrome 3 (1.4%)	hypertrophy 10 (4.7%)
Cardiac medication		Right bundle branch block	moderate to severe dilation 4 (1.9%)
Diuretics	19 (8.8%)	complete 100 (46.5%)	right ventricle
ACE-Inhibitors	58 (27.0%)	incomplete 35 (16.3%)	hypertrophy 14 (6.5%)
Digoxin	8 (3.7%)	Pacemaker	moderate to severe dilation 3 (1.4%)
β-Blocker	9 (4.2%)	PM-implantation 16 (7.4%)	left AV-valve regurgitation
Phenprocoumon	8 (3.7%)	PM-associated procedures	none-I° 142 (66.0%)
Pulmonary Hypertension	8 (3.7%)	1-2 procedures 7 (3.3%)	I-II° 62 (28.8%)
		3-4 procedures 5 (2.3%)	>II° 11 (5.1%)
			right AV-valve regurgitation
			none-I° 193 (89.8%)
			I-II° 20 (9.3%)
			>II° 2 (0.9%)

Supplementary Material S1 Overview of the clinical status of surviving patients at their last follow-up. ACE, angiotensin-converting enzyme; AV, atrioventricular; LVOTO, left ventricular outflow tract obstruction; NYHA, New York Heart Association; PM, pacemaker.

Intraoperative Findings at reoperation n=45

	n (%)
dysplastic leaflet tissue	22 (48.9%)
residual cleft	14 (31.1%)
leaflet perforation	11 (24.4%)
repair dehiscence	9 (20.0%)
abnormal leaflet pliability	8 (17.8%)
endocarditis	5 (11.1%)
stenosis after prior repair	1 (2.2%)

Supplementary Material S2 Intraoperative findings at reoperation.